On August 2, 2023 Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, reported that it has provided a $15 million venture loan facility to Tallac Therapeutics, Inc. ("Tallac"), of which $5 million has been initially funded (Press release, Tallac Therapeutics, AUG 2, 2023, View Source [SID1234633678]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Tallac is developing multiple novel immunotherapies to fight cancer. Tallac’s innovative Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform enables systemic delivery of differentiated TLR9 agonists to activate a specific anti-cancer immune response for various solid tumor malignancies. Tallac is backed by premier investors including venBio, Lightstone Ventures, Morningside and MRL Ventures Fund. The company will use the loan proceeds for general growth and working capital purposes.
"Tallac is advancing new immunotherapies that may make a tremendous difference in the ongoing fight against cancer," said Gerald A. Michaud, President of Horizon. "Through the development of antibody conjugate-based therapeutics, Tallac’s best-in-class therapies attempt to trigger innate and adaptive immune responses to best address the needs of patients. We are pleased to support Tallac’s continued work and its vital mission."
"We are pleased to have Horizon’s support as we continue to make excellent progress in our TRAAC platform and programs," said Hong I. Wan, Ph.D., president, CEO and co-founder of Tallac Therapeutics. "We are excited to further progress our lead program, TAC-001, in the clinic and to advance additional agents to find difficult-to-treat cancers."